Analysis of GGAA-Microsatellites in Ewing Sarcoma
N/A
50 Years
Both
Sarcoma
Trial Information
Analysis of GGAA-Microsatellites in Ewing Sarcoma
OBJECTIVES:
- To describe the spectrum of GGAA-microsatellite polymorphisms at specific loci in
genomic DNA prepared from Ewing sarcoma tumor specimens.
- To determine if there are differences in GGAA-microsatellite polymorphisms in genomic
DNA prepared from Ewing sarcoma tumor specimens as compared to non-afflicted European
and African normal genomic DNA.
- To determine if GGAA-microsatellite polymorphisms at specific loci in genomic DNA
prepared from Ewing's sarcoma tumor specimens correlates with disease outcome in
patients treated on COG protocol AEWS0031.
- To determine whether whole-genome amplification introduces alterations in
GGAA-microsatellites as compared to non-amplified genomic DNA.
OUTLINE: Genomic PCR is used to amplify the microsatellites in the NR0B1 and GSTM4
promoters. In addition to determining microsatellite size, each microsatellite is sequenced
following cloning into the pCR4 vector (Invitrogen) using standard topoisomerase cloning
protocols.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Specimens from patients with Ewing sarcoma used for protocol COG-AEWS08B1
- Obtained from patient samples taken from patients enrolled on COG-AEWS0031
- Whole genome-amplified DNA will be used
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Event-free survival
Safety Issue:
No
Principal Investigator
Stephen Lessnick, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Utah
Authority:
United States: Federal Government
Study ID:
CDR0000717540
NCT ID:
NCT01480518
Start Date:
December 2011
Completion Date:
Related Keywords:
- Sarcoma
- localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
- Sarcoma, Ewing's
- Neuroectodermal Tumors, Primitive, Peripheral
- Sarcoma
Name | Location |
|---|
